JUNS Stock Analysis: Buy, Sell, or Hold?
JUNS - Jupiter Neurosciences, Inc. Common Stock
$0.23
-0.01 (-2.34%)
▼
5d:
+2.04%
30d:
-30.91%
90d:
-37.95%
BUY
MODERATE Confidence
Analysis Updated: Jun 17, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When JUNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: JUNS shows positive signals but monitor for confirmation. Market pricing in 26.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: JUNS shows positive signals but monitor for confirmation. Market pricing in 26.7% decline. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: JUNS is currently trading at $0.23, which is considered slightly low relative to its 30-day fair value range of $0.22 to $0.31. From a valuation perspective, the stock is trading at a discount (Forward PE: 3.8) compared to its historical average (9.7). Remarkably, the market is currently pricing in an annual earnings decline of 26.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.22, while resistance sits at $0.29.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+12966.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, JUNS is in a strong downtrend. Immediate support is located at $0.22, while resistance sits at $0.29.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $30.00 (+12966.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.22 -
$0.31
Company Quality Score
54/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: Trading 12966.2% below Wall St target ($30.00)
Trading Range Analysis
30-Day Trading Range
$0.22 -
$0.31
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.22
Resistance Level
$0.29
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
3.83
Wall Street Target
$30.00
(+12966.2%)
Valuation Discount vs History
-26.7% cheaper
PE vs Historical
3.8 vs 9.7
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-26.7%
(market-implied from PE analysis)
1-Year Target
$0.21
(-10%)
2-Year Target
$0.19
(-19%)
3-Year Target
$0.17
(-27%)
3-Yr Target (if PE normalizes)
(PE: 4→10)
$0.42
(+85%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 3.8 to 9.7
Stabilization Target:
$0.58
(+153.5%)
PE Expansion Potential:
+153.5%
Share & Embed Analysis
Last updated: June 17, 2026 9:40 PM ET
Data refreshes hourly during market hours. Next update: 10:40 PM
Data refreshes hourly during market hours. Next update: 10:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JUNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 61 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 66 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 55 HOLD |
